What do Kagocel tablets help with? Let's get acquainted with the new generation antiviral drug - Kagocel: description and instructions for use for children Kagocel instructions for use for prevention
Kagocel is an original domestic antiviral drug belonging to the group of inducers (stimulators) of the synthesis of the immune protein interferon. The active component here is the sodium salt of the copolymer, the length of the chemical formula of which does not allow it to fit into the “Procrustean bed” of this information article. Used for the treatment and prevention of influenza and ARVI. It has a double effect: it exhibits direct antiviral activity in combination with a pronounced immunomodulatory effect. Kagocel causes the formation of the so-called. “late” interferons alpha and beta, which are known to be the most effective against viruses. The drug stimulates the production of interferons for a long time: when using a single dose of Kagocel, the therapeutic level of interferons is maintained in the patient’s blood for 7 days, which makes it possible to effectively use it both for the treatment of influenza and ARVI, and for their prevention. Along with other drugs of this pharmacological group, Kagocel combines well with immunostimulants, antibacterial drugs, means of chemotherapy. The first clinical studies of Kagocel were carried out by scientists from the Influenza Research Institute (St. Petersburg), the Virology Research Institute (Moscow) and the Military Medical Academy (St. Petersburg). The study involved about 600 patients with influenza and ARVI. For their treatment, the following regimen was used: 2 tablets of Kagocel 3 times a day for the first 2 days, and in the next 2 - 1 tablet 3 times a day. It was found that when Kagocel is used in the first 4 days after infection, the drug has a powerful therapeutic effect against influenza caused by viruses A/H1N1, A/H3N2 and B: a decrease in body temperature in the first 2-3 days was noted by 70% of patients, while in the placebo group there were only 25% of such patients. The disappearance of signs of intoxication in the same period was observed in 64% and 20% of patients, respectively. Kagocel is also effective against influenza in combination with bacterial sore throat: 90% of patients receiving the drug as part of combination therapy showed normalization of body temperature on days 2-3 and elimination of signs of inflammation in the oral cavity and pharynx, while in the placebo group similar changes were observed only in 35% of patients.
The positive effect of Kagocel on the course of other acute respiratory viral infections (adenoviral disease, parainfluenza) is expressed in a reduction in the period of fever, mitigation and complete elimination of signs of intoxication in 85% of patients. According to the results of laboratory and clinical trials the drug does not cause negative effects adverse reactions, does not have an immunosuppressive effect on tissue and humoral immunity. Thus, Kagocel is a highly effective remedy for the prevention and treatment of influenza and acute respiratory viral infections caused by various viral strains, incl. pandemic. The drug has a number of advantages compared to others medicines: optimal safety profile, absence of clinically significant adverse reactions, ease of use. It is important that Kagocel has a direct antiviral effect, even with a relatively late start of use - 3-4 days from the moment the first signs of infection appear. Kagocel does not accumulate in the body and does not have carcinogenic, teratogenic, embryotoxic or mutagenic properties. In order to prevent the incidence of influenza and ARVI, the drug can be used at any time, incl. and as a means of emergency prevention after direct contact with a carrier of infection.
Kagocel is available in tablets. Adult patients with therapeutic purpose Prescribe 2 tablets 3 times a day (the first 2 days) and 1 tablet 3 times a day (the next 2 days). Thus, the total duration of the drug course is 4 days. Prevention viral infections is carried out in seven-day courses: 2 tablets 1 time per day (the first 2 days), after which a 5-day break is taken and the course is repeated. Such prevention can be carried out for up to several months.
Pharmacology
Antiviral drug, inducer of interferon synthesis. The active substance is the sodium salt of a copolymer of (1→4)-6-0-carboxymethyl-β-D-glucose, (1→4)-β-D-glucose and (21→24)-2,3,14,15 ,21,24,29,32-octahydroxy-23-(carboxymethoxymethyl)-7,10-dimethyl-4, 13-di(2-propyl)-19,22,26,30,31-pentaoxaheptacyclo dotriaconta-1,3 ,5(28),6,8(27), 9(18),10, 12(17), 13,15-decaene.
Causes the formation in the body of so-called late interferon, which is a mixture of alpha and beta interferons with high antiviral activity. Kagocel ® causes the production of interferon in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel ® is taken orally, the interferon titer in the blood serum reaches maximum values after 48 hours. The body's interferon response to the administration of Kagocel ® is characterized by prolonged (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of interferon accumulation in the intestine when taking the drug orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, the interferon content reaches high values only 48 hours after taking the drug Kagocel ®, while in the intestine the maximum interferon production is observed after 4 hours.
Kagocel ® when prescribed in therapeutic doses is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.
The greatest effectiveness in treatment with Kagocel ® is achieved when it is prescribed no later than the 4th day from the start acute infection. For preventive purposes, the drug can be used at any time, incl. and immediately after contact with an infectious agent.
Pharmacokinetics
Suction and distribution
When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. 24 hours after oral administration, the drug accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content in the brain is explained by the high molecular weight of the drug, which impedes its penetration through the BBB. In the blood plasma, the drug is found predominantly in bound form: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
With daily repeated administration of the drug, V d varies widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes.
Removal
It is excreted mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% in feces and 10% in urine. The drug was not detected in exhaled air.
Release form
The tablets are cream to brown, round, biconvex, interspersed.
Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, ludipress (directly compressed lactose with the composition: lactose monohydrate, povidone (kollidon 30), crospovidone (kollidon CL)) - to obtain a tablet weighing 100 mg.
10 pcs. - contour cellular packaging (1) - cardboard packs.
Dosage
The drug is taken orally.
For the treatment of influenza and ARVI, adults are prescribed 2 tablets in the first 2 days. 3 times a day, in the next 2 days - 1 tablet. 3 times/day. A total of 18 tablets per course lasting 4 days.
Prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 2 tablets. 1 time/day, break for 5 days. Then the cycle is repeated. The duration of the preventive course varies from 1 week to several months.
For the treatment of herpes, 2 tablets are prescribed. 3 times/day for 5 days. In total, for a course lasting 5 days - 30 tablets.
For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed 1 tablet in the first 2 days. 2 times a day, in the next 2 days - 1 tablet. 1 time/day A total of 6 tablets per course lasting 4 days.
For the treatment of influenza and ARVI, children aged 6 years and older are prescribed 1 tablet in the first 2 days. 3 times a day, in the next 2 days - 1 tablet. 2 times/day. A total of 10 tablets per course lasting 4 days.
In children aged 3 years and older, prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 1 tablet. 1 time/day, break for 5 days, then repeat the cycle. The duration of the preventive course is from 1 week to several months.
Overdose
Treatment: in case of accidental overdose, it is recommended to prescribe plenty of fluids and induce vomiting.Interaction
When using the drug Kagocel ® simultaneously with other antiviral drugs, immunomodulators and antibiotics, an additive effect is observed.
Side effects
Possible: allergic reactions.
The patient should inform the doctor about the development of any side effects.
Indications
- prevention and treatment of influenza and other acute respiratory viral infections in adults and children aged 3 years and older;
- treatment of herpes in adults.
Contraindications
- pregnancy;
- lactation period (breastfeeding);
- children under 3 years of age;
- lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- hypersensitivity to the components of the drug.
Features of application
Use during pregnancy and breastfeeding
Due to the lack of necessary clinical data, Kagocel ® is not recommended for use during pregnancy and lactation (breastfeeding).
Impact on the ability to drive vehicles and operate machinery
Effect of the drug on the ability to drive vehicles, the mechanisms have not been studied.
Special instructions
To achieve a therapeutic effect, taking Kagocel ® should be started no later than 4 days from the onset of the disease.
Kagocel ® combines well with other antiviral drugs, immunomodulators and antibiotics.
Respiratory diseases, frequent colds, flu... Any child, even with proper care, can avoid these diseases. His immunity is still developing and it is difficult for him to resist viral attacks.
For most parents, there is no more pressing problem than finding a medicine that will help cope with a cold and prevent its occurrence in the future.
The antiviral drug Kagocel belongs to the group of drugs that promote the production of interferon. It relieves babies from colds and provides protection for the developing body.
At what age can Kagocel be given to children, and how often should the drug be taken? We will consider the answers to these questions and instructions for using Kagocel for children in detail in our article.
Composition, effect on the children's body
Kagocel – antiviral agent with low toxicity. Pediatricians note its fairly high safety. The medicine acts equally effectively at any stage of the disease.
Contains vegetable active substance- a copolymer that is extracted from cotton.
The active substance stimulates the body's production of interferon protein. Interferon functions include:
- preventing the spread of viruses;
- restoration of damaged cells;
- increasing cell immunity to viral attacks;
- relieving cold symptoms;
- increasing immunity.
The advantage of this product is that it does not accumulate in the body and does not cause side effects. The medicine is released in tablets for oral administration. Each tablet contains 12 mg of active ingredient.
Read about how the drug for the treatment and prevention of ARVI and influenza works in drops for children.
Indications
According to statistics, children of preschool and junior school age suffer 5-8 acute respiratory infections per year. In cities, this figure increases to 10-12 cases annually.
Kagocel successfully fights viruses of various origins. The drug is prescribed for the treatment and prevention of the following diseases:
According to the results of clinical studies, the use of Kagocel can reduce the number of children suffering from ARVI by 3 times.
Kagocel is also effective in cases where children in children's groups experience cases of spreading dangerous disease- chickenpox. Treatment will eliminate the virus initial stage infection. If symptoms chickenpox still appeared, taking the medicine will speed up recovery.
Kagocel only promotes rapid recovery. The use of the drug should not cause the cancellation of other treatment methods.
Learn how to protect your child from colds and flu during illness season in this video:
Contraindications
Despite the high safety of the product, it is necessary to highlight contraindications:
- age up to 3 years;
- tendency to allergic reactions;
- lactose intolerance;
- hypersensitivity to the components of the drug.
With great caution, Kagocel is prescribed to children suffering from renal, endocrine, neurological and mental diseases.
Babies included in these risk groups use without a doctor's recommendation is not recommended.
In case of an overdose, headaches, abdominal pain, nausea, vomiting, and anxiety may occur. If these symptoms occur, the patient's stomach is washed and given activated carbon at the rate of 1 tablet per 10 kg of weight.
How to take, dosage
The product overcomes viral infections, prevents them from gaining a foothold inside the body, and limits their reproduction. The level of interferon increases 3-4 hours after administration, and the maximum effect is achieved after 2 days.
How to drink Kagocel correctly? For viral infections in patients over 6 years of age, it is recommended to take 1 tablet 3 times a day before meals or a few hours after it.
After 2 days, the dose is reduced to 1 tablet 2 times a day. The course of treatment lasts 4 days.
If Kagocel is taken for prophylactic purposes, the dose for children is 1 tablet once a day.
After two days, a break of five days is necessary, then the drug is repeated. To clarify the required dosage, consult a doctor.
Kagocel is taken orally, without chewing, with a few sips of water. You should carefully monitor your intake time. If the medicine was not taken on time, double dosage is best avoided. The medicine is not recommended during meals, since the process of digesting food reduces its effectiveness.
Why is the drug not recommended for children under 3 years of age? This limitation is due to the fact that patients in this age category did not participate in drug trials.
Children 3-6 years old take 1 tablet 2 times a day (2 days), then 1 tablet a day (another 2 days).
Interaction with other substances
Kagocel goes well with immunostimulants and antibiotics. The drug also complements the effectiveness of other antiviral drugs.
The therapeutic effect of the drug will be low if you start taking it later than 4 days from the onset of symptoms of the disease. If the product is used for prophylaxis, there are no restrictions on the time of administration.
Price, conditions and shelf life
The drug is stored in a dry place, out of reach of children, at a temperature not exceeding 25 °C. Shelf life – 2 years. The price of the drug is from 217 to 250 rubles.
In our material we will tell you about a popular antipyretic drug for children - you will learn about dosage rules and contraindications.
What effect do Nurofen suppositories have for children: read reviews on the use of the drug to reduce fever.
Tablets - 1 tablet:
- Active substance: Kagocel® 12 mg;
- Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - to obtain a tablet weighing 100 mg.
Tablets, 12 mg.
10 tablets per blister pack made of polyvinyl chloride/polyvinylidene chloride film and aluminum foil with a heat-sealable coating.
1, 2 or 3 strip strips along with instructions for use are placed in a pack.
Description of the dosage form
Tablets from white with a brownish tint to light brown, round, biconvex, interspersed with brown.
Pharmacological action
Kagocel is a highly effective new generation antiviral drug.
Pharmacokinetics
24 hours after administration to the body, Kagocel® accumulates mainly in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the blood-brain barrier. In the blood plasma the drug is found predominantly in bound form.
With daily repeated administration of Kagocel®, the volume of distribution varies widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
Excretion: the drug is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% through the kidneys. The drug was not detected in exhaled air.
Pharmacodynamics
The main mechanism of action of Kagocel® is the ability to induce the production of interferons. Kagocel® causes the formation in the human body of so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes the production of interferons in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel® is taken orally, the titer of interferons in the blood serum reaches maximum values after 48 hours. The body's interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine when Kagocel® is taken orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, the production of interferons reaches high values only 48 hours after taking Kagocel®, while in the intestine the maximum production of interferons is observed after 4 hours.
Kagocel®, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.
The greatest effectiveness in treatment with Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.
Instructions
Inside, regardless of food intake.
For the treatment of influenza and ARVI, adults are prescribed 2 tablets 3 times a day in the first two days, and one tablet 3 times a day in the next two days. A total of 18 tablets per course, course duration – 4 days.
Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days - 2 tablets once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. A total of 30 tablets per course, course duration – 5 days.
For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time a day. A total of 6 tablets per course, course duration – 4 days.
For the treatment of influenza and acute respiratory viral infections, children over 6 years of age are prescribed 1 tablet 3 times a day in the first two days, and one tablet 2 times a day in the next two days. A total of 10 tablets per course, course duration – 4 days.
Prevention of influenza and ARVI in children aged 3 years and older is carried out in 7-day cycles: two days - 1 tablet once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.
Indications for use Kagocel
Kagocel® is used in adults and children over the age of 3 years as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.
Contraindications to the use of Kagocel
- Pregnancy and lactation;
- Age up to 3 years;
- Hypersensitivity to the components of the drug;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Kagocel Use during pregnancy and children
Due to the lack of necessary clinical data, Kagocel® is not recommended for use during pregnancy and lactation.
Kagocel Side effects
Possible development allergic reactions.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects, not listed in the instructions, inform your doctor.
Drug interactions
Kagocel® combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).
Dosage Kagocel
Inside. For the treatment of influenza and ARVI, adults are prescribed 2 tablets. 3 times a day in the first 2 days, in the next 2 days - 1 tablet. 3 times a day. A total of 18 tablets per course of treatment, course duration - 4 days.
Prevention of respiratory viral infections in adults is carried out in 7-day cycles: 2 days, 2 tablets. Once a day, then a break for 5 days and the cycle is repeated. The duration of the preventive course is from 1 week to several months. For the treatment of herpes, adults are prescribed 2 tablets. 3 times a day for 5 days.
A total of 30 tablets per course of treatment, course duration - 5 days. For the treatment of influenza and ARVI, children over 6 years of age are prescribed 1 tablet. 3 times a day in the first 2 days, in the next 2 days - 1 tablet. 2 times a day. A total of 10 tablets per course of treatment, course duration - 4 days.
Overdose
Precautions
To achieve a therapeutic effect, Kagocel® should be taken no later than the fourth day from the onset of the disease.
Impact on the ability to drive vehicles and operate machinery
The effect of the drug on the ability to drive vehicles and operate machinery has not been studied.
Kagocel is an antiviral agent that has immunomodulatory and radioprotective effects and induces the production of interferon.
The drug has antimicrobial, antiviral, immunostimulating and radioprotective effects. The mechanism of action is based on its ability to stimulate the synthesis of endogenous interferon proteins, in particular, under the influence of the drug there is an increase in the amount of alpha, beta and gamma interferons.
Kagocel helps increase the production of interferon in various cells involved in the formation of the immune response, including macrophages, granulocytes, T- and B-lymphocytes, endothelial cells and fibroblasts. Interferons are specific proteins that have pronounced antiviral activity; due to the activation of the enzymes protein kinase and adelyl synthetase, interferons inhibit the synthesis of viral proteins and viral RNA. In addition, interferons have direct and indirect antitumor activity.
After a single oral administration of Kagocel, the maximum production of interferon in the intestine is observed after 4 hours, and the maximum concentration of interferon in the blood plasma is achieved within 48 hours, while the high level of interferon in the blood plasma persists up to 4-5 days after use.
In therapeutic doses it has no toxic effect on the body, practically does not accumulate in organs and tissues, and does not have a teratogenic, mutagenic or embryotoxic effect.
In order to achieve a therapeutic effect from taking Kagocel, you should start taking it no later than the 4th day from the appearance of the first symptoms of the disease.
For prevention, it can be prescribed at any time, including immediately after contact with the infectious agent.
Indications for use
What does Kagocel help with? According to the instructions, the drug is prescribed in the following cases:
- prevention and treatment of influenza and other acute respiratory viral infections in adults and children over 3 years of age;
- treatment of herpes in adults.
Instructions for use Kagocel, dosage
For adults
For the treatment of influenza and ARVI, 2 tablets 3 times a day are prescribed in the first 2 days, 1 tablet 3 times a day in the next 2 days. A total of 18 tablets per course lasting 4 days.
Prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 2 tablets \ 1 time per day, break for 5 days. Then the cycle is repeated. The duration of the preventive course varies from 1 week to several months.
Kagocel for children aged 6 years and older
For the treatment of influenza and ARVI, it is prescribed in the first 2 days - 1 tablet \ 3 times a day, in the next 2 days - 1 tablet \ 2 times a day. A total of 10 tablets per course lasting 4 days.
Prevention of influenza and ARVI is carried out in 7-day cycles: 2 days - 1 tablet \ 1 time per day, break for 5 days, then the cycle is repeated. According to the instructions for use, Kagocel is taken from 1 week to several months (for preventive purposes).
The drug combines well with antibiotics, immunomodulators and other antiviral drugs.
Side effects
The instructions warn about the possibility of developing the following side effects when prescribing Kagocel:
- the development of allergic reactions of individual intolerance is possible.
Contraindications
Kagocel is contraindicated in the following cases:
- increased individual sensitivity to the components of the drug;
- lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
- age up to 3 years;
- period of pregnancy and lactation.
Overdose
Overdose may cause nausea and abdominal pain. It is recommended to drink plenty of fluids and induce vomiting.
Analogues of Kagocel, price in pharmacies
If necessary, you can replace Kagocel with an analogue in terms of therapeutic effect - these are the following drugs:
- Anaferon,
- Cytovir-3,
- Amizon,
When choosing analogues, it is important to understand that the instructions for use of Kagocel, the price and reviews of drugs with similar effects do not apply. It is important to consult a doctor and not change the drug yourself.
Price in Russian pharmacies: Kagocel 12 mg tablets 10 pcs. – from 218 to 253 rubles, according to 725 pharmacies.
Store in a dry, dark place, out of reach of children, at temperatures up to 25°C. Shelf life – 2 years. Conditions for dispensing from pharmacies - without a prescription.
What do the reviews say?
Numerous reviews about Kagocel are mostly positive - they note the effectiveness and the ability to completely eliminate the symptoms of acute respiratory infections in just a week. Doctors recommend using Kagocel for prevention viral diseases, including influenza. Treatment requires the use of complex therapy.
Many parents in their reviews especially note the fact that Kagocel can be used from 3 years of age. Also on the list of advantages is the absence of severe adverse reactions (possible development of a minor allergy), neutral taste and smell of the drug.
Description of the dosage form
Pills: cream to brown, round, biconvex with inclusions.
Pharmacological action
Pharmacological effects - immunomodulatory, antiviral.
Pharmacodynamics
The main mechanism of action of the drug Kagocel® (hereinafter referred to as Kagocel) is considered to be the ability to induce the production of interferon. Kagocel causes the formation of the so-called in the human body. late interferon, which is a mixture of alpha and beta interferons with high antiviral activity. Kagocel causes the production of interferon in almost all cell populations involved in the body's antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel is taken orally, the interferon titer in the blood serum reaches maximum values after 48 hours. The body's interferon response to Kagocel administration is characterized by long-term (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of interferon accumulation in the intestine when Kagocel is taken orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, interferon production reaches high values only 48 hours after taking Kagocel, while in the intestine the maximum interferon production is observed after 4 hours.
Kagocel, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.
Maximum effectiveness in treatment with Kagocel is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, incl. and immediately after contact with an infectious agent.
Pharmacokinetics
24 hours after administration to the body, Kagocel accumulates, as a rule, in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel in the brain is explained by the high molecular weight of the drug, which impedes its penetration through the BBB. In the blood plasma the drug is usually found in bound form.
With daily repeated administration of Kagocel, the Vd of the drug fluctuates widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes. When taken orally, about 20% of the administered dosage of the drug enters the general bloodstream. The absorbed drug circulates in the blood, as a rule, in a form associated with macromolecules: 47% with lipids, 37% with proteins. The unbound portion of the drug is about 16%.
Removal: The drug is eliminated from the body, as a rule, through the intestines: 7 days after administration - 88% of the administered dosage, incl. 90% - through the intestines and 10% - through the kidneys. The drug was not detected in exhaled air.
Indications for the drug Kagocel®
prevention and treatment of influenza and other acute respiratory viral infections (ARVI) in adults and children over 3 years of age;
treatment of herpes in adults.
Contraindications
hypersensitivity to the components of the drug;
lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
pregnancy;
lactation period;
age up to 3 years.
Use during pregnancy and breastfeeding
Due to the lack of necessary clinical data, Kagocel is not recommended for use during pregnancy and lactation.
Side effects
Allergic reactions are likely to develop.
If any of the side effects indicated in the instructions get worse, or the patient notices any other side effects not listed in the instructions, you should inform your doctor.
Interaction
Kagocel combines well with other antiviral drugs, immunomodulators and antibiotics (additive result).
Directions for use and doses
Inside.
For the treatment of influenza and ARVI in adults 2 tablets are prescribed. 3 times a day in the first 2 days, in the next 2 days - 1 tablet. 3 times a day. A total of 18 tablets per course of treatment, course duration - 4 days.
Prevention of influenza and ARVI in adults carried out in 7-day cycles: 2 days, 2 tablets. Once a day, 5 days break, then repeat the cycle. The duration of the preventive course is from 1 week to several months.
For the treatment of herpes in adults 2 tablets are prescribed. 3 times a day for 5 days. A total of 30 tablets per course of treatment, course duration - 5 days.
For the treatment of influenza and acute respiratory viral infections in children aged 3 to 6 years 1 tablet is prescribed. 2 times a day in the first 2 days, in the next 2 days - 1 tablet. 1 time per day. There are 6 tables in total per course, course duration is 4 days.
For the treatment of influenza and acute respiratory viral infections in children over 6 years of age 1 tablet is prescribed. 3 times a day in the first 2 days, in the next 2 days - 1 tablet. 2 times a day. A total of 10 tablets per course of treatment, course duration - 4 days.